18.79  -0.1 (-0.53%)		06-09 16:00
Open: 20.98 High: 22 Volume: 551,797		Pre. Close: 18.89 Low: 18.65 Market Cap: 67(M)

Short term
Mid term
Targets	6-month :	28.03	1-year :	32.74
Resists	First :	24	Second :	28.03
Pivot price	17.63
Supports	First :	16.75	Second :	12.27
MAs	MA(5) :	19.82	MA(20) :	17.32
	MA(100) :	11.86	MA(250) :	7.48
MACD	MACD :	1.6	Signal :	1.6
%K %D	K(14,3) :	51.4	D(3) :	65.4
RSI	RSI(14): 57.4
52-week	High :	24	Low :	2.73

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ CHRN ] has closed below upper band by 36.9%. Bollinger Bands are 119.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	22.02 - 22.2	22.2 - 22.32
Low:	18.33 - 18.5	18.5 - 18.61
Close:	18.57 - 18.83	18.83 - 19.01

Ekso Bionics Holdings, Inc., which began operations on January 30, 2012, and is headquartered in San Rafael, California, specializes in developing, refining, and marketing advanced exoskeleton technology. These innovative systems are currently applied in both the medical and industrial fields.

Wed, 20 May 2026
ChronoScale (CHRN) shifts executive phantom PSU payouts to stock and cash - Stock Titan

Mon, 18 May 2026
ChronoScale (CHRN) director Wes Cummins granted 200,000 restricted shares in equity award - Stock Titan

Mon, 18 May 2026
ChronoScale Corp (CHRN) director awarded 200,000 restricted shares vesting over two years - Stock Titan

Mon, 18 May 2026
Richard Nottenburg awarded 200K ChronoScale (CHRN) restricted shares - Stock Titan

Mon, 18 May 2026
ChronoScale (CHRN) director awarded 200,000 restricted shares vesting over two years - Stock Titan

Mon, 18 May 2026
[Form 4] EKSO BIONICS HOLDINGS, INC. Insider Trading Activity - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Specialties
Shares Out	143 (M)
Shares Float	0 (M)
Held by Insiders	97.5 (%)
Held by Institutions	1 (%)
Shares Short	424 (K)
Shares Short P.Month	0 (K)

EPS	-0.51
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	27.63
Profit Margin	-86.2 %
Operating Margin	-39.5 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	-0.05
Sales Per Share	0.58
EBITDA (p.s.)	0.17
Qtrly Earnings Growth	0 %
Operating Cash Flow	-7 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	-36.85
PEG Ratio	0
Price to Book value	0.67
Price to Sales	31.86
Price to Cash Flow	-372.4

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.